PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. THE THE TOWN Application Number 10/001.863 TRANSMITTAL Filing Date November 19, 2001 **FORM** First Named Inventor James G. Karras et a (to be used for all correspondence after initial filing) Art Unit 1635 **Examiner Name** Janet L. Epps Total Number of Papers in This Submission One Attorney Docket Number ISIS0063-100 ENCLOSURES (check all that apply) After Allowance Communication to Assignment Papers Fee Transmittal Form (for an Application) Group Appeal Communication to Board of Fee Attached Drawing(s) Appeals and Interferences Amendment / Response To Appeal Communication to Group Licensing-related Papers Restriction Requirement (Appeal Notice, Brief, Reply Brief) Petition After Final Proprietary Information Petition to Convert to a Affidavits/declaration(s) Status Letter Provisional Application Power of Attorney, Revocation Other Enclosure(s) Extension of Time Request Change of Correspondence Address (please identify below): Terminal Disclaimer Express Abandonment Request Request for Refund Information Disclosure Statement CD, Number of CD(s) Certified Copy of Priority Remarks Document(s) Express Mail Label No. EV146 601 450US Response to Missing Parts/ Date of Deposit: July 7, 2003 Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Quan Le Nguyen, Reg. No. 46,957 Cozen O'Connor, P.C. Individual name Signature July 7, 2003 Date **CERTIFICATE OF MAILING** I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail Service in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Typed or printed name Quan L. Nguyen, Reg. No. 46,957

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

July 7, 2003

Signature

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Karras et al.

Confirmation No. 1531

Serial No.: 10/001,863

Group Art Unit: 1635

Filed: 11/19/2001

Examiner: Epps, Janet L.

Title: Antisense Modulation of Toll-Like Receptor 4 Expression

ECH CHILL TOO SON EXPRESS MAIL LABEL NO. EV146 601 450US

DATE OF DEPOSIT: July 7, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

This paper is filed in response to the Office Action dated June 6, 2003.

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

STATUS OF CLAIMS

Please add new claims 21-27:

Claim 1 (original) A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding Toll-like receptor 4, wherein said compound specifically hybridizes with said nucleic acid molecule encoding Toll-like receptor 4 and inhibits the expression of Toll-like receptor 4.

Claim 2 (original) The compound of claim 1 which is an antisense oligonucleotide